The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 2.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (6 analysts) rates it strong buy, with a mean price target of $110.
Axos Financial, Inc.
AX · the NYSE · USD · Market cap $5.3B · 1,989 employees
Axos Financial, Inc., together with its subsidiaries, operates as a consumer and business banking provider in the United States.
FAIL · Does not pass the screenAt the last full screen
2026-09-10
Screened 2026-09-10 · the tape above runs as of 22:12 UTC · 11 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
This name holds its markdown label.
Axos Financial, Inc. holds its Markdown at $93.72. Consolidating, no directional conviction, held for 1 days.
| Phase | Markdown · caution |
| Quantitative state | Consolidating, no directional conviction, held for 1 days |
| Price at the screen | $93.72 |
| Valuation | 11.05 trailing · 8.65 forward price to earnings |
| Values screen | FAIL · score 30.0 |
| Beta | 1.22 |
Five Screens, Shown in Full
Does not pass. Prohibited keyword in sector/industry: bank
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Excluded | Core business clean | Prohibited keyword in sector/industry: bank | Fail |
| Debt load | Excluded | Below 33% | Interest-bearing debt is of its assets, above the one-third ceiling the screen allows. | Fail |
| Interest-bearing cash | Excluded | Below 33% | Interest-bearing cash and securities are of assets, above the one-third limit. | Fail |
| Receivables | Excluded | Below 49% | Money owed to the company is of assets, above the 49% limit. | Fail |
| Revenue purity | Excluded | Below 5% | of revenue comes from non-compliant sources, over the 5% line. | Fail |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is WorthThe Fair Value Range
Fair value range in USD, drawn from the 2026-09-10 screen. The gold marker is the market price at the same screen. A 36.6% margin of safety to the base estimate.
Third-party analyst targets: 7 covering, consensus None. The average target sits +28% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-10 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsBanks Look Cheap But Ethics Block The Door
Everyday Americans move pay cheques and business loans through regional banks without a second thought. Axos clears the numbers test with 19% revenue growth, a 36% profit margin and 17% ROE, yet it lands on the prohibited list from the first filter. We pass for that single reason and nothing else.
The forward multiple sits at 10.4 times and the shares trade below our fair value, but the ethical screen exists to stop exactly this kind of holding. Sector rules override valuation every time.
Standard bank risks around credit cycles and interest-rate swings remain, yet the ethical flag is what keeps us out. Analysis, not advice.
| Forward P/E | 8.7xcheap for a company growing this fast |
| Trailing P/E | 11.1xreasonably valued |
| EPS, trailing | 8.48 |
| EPS, forward | 10.83 |
| Revenue growth | +18.1%steady growth |
| Profit margin | 35.5%highly profitable on every dollar of sales |
| Return on equity | 16.8%a solid return on shareholder capital |
| Beta | 1.22moves a little more than the market |
| Short interest, float | 0.07% |
| 52-week range | 74.89 - 105.74 |
| Market cap | $5.3B |
| Employees | 1,989 |
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeAX trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 10.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (6 analysts) rates it strong buy, with a mean price target of $110.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (6 analysts) rates it strong buy, with a mean price target of $110.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
Screened names in the same industry · explore each on its own page.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 9 Apr2026 | Josh Gottheimer | Democrat | sell | 1K–15K |
| 8 May2026 | Rick Allen | Republican | buy | 1K–15K |
| 4 Nov2025 | Tim Sheehy | Republican | sell | 50K–100K |
| 4 Nov2025 | Tim Sheehy | Republican | sell | 50K–100K |
| 4 Nov2025 | Tim Sheehy | Republican | sell | 50K–100K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $85.49 | +3.1% | · | $1,031 | +3.1% |
| 2 months | $92.50 | -4.7% | · | $953 | -4.7% |
| 3 months | $84.66 | +4.1% | · | $1,041 | +4.1% |
| 6 months | $85.68 | +2.9% | · | $1,029 | +2.9% |
| 1 year | $72.99 | +20.8% | · | $1,208 | +20.8% |
| 2 years | $52.14 | +69.0% | · | $1,690 | +69.0% |
| 3 years | $41.52 | +112.3% | · | $2,123 | +112.3% |
| 5 years | $48.48 | +81.8% | · | $1,818 | +81.8% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever AX does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.